Table 2 GRADE evidence profile
No. of patients | Effect | Quality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
NO. of studies | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Dexamethasone | Ondansetron | Relative(95 % CI) | Absolute | |
7 | No serious risk of bias | No serious inconsistency | No serious indirectness | Serious | None | 101/303(33.3 %) | 112/305(36.7 %) | RR 0.91(0.72-1.12) | 33 fewer per 1000 (from 103 fewer to 44 more) | MODERATE |
5 | No serious risk of bias | No serious inconsistency | No serious indirectness | Serious | None | 47/163(28.8 %) | 39/165(23.6 %) | RR 1.25(0.84-1.76) | 59 more per 1000 (from 38 fewer to 180 more) | MODERATE |
5 | No serious risk of bias | No serious inconsistency | No serious indirectness | Serious | None | 13/163(8 %) | 26/165(15.8 %) | RR 0.48(0.25-0.92) | 82 fewer per 1000 (from 13 fewer to 118 more) | MODERATE |
7 | No serious risk of bias | No serious inconsistency | No serious indirectness | Serious | None | 65/303(21.5 %) | 73/305(23.9 %) | RR 0.89(0.64-1.19) | 26 fewer per 1000 (from 86 fewer to 45 more) | MODERATE |